Jubilant Ingrevia Limited
NSE: JUBLINGREA BSE: JUBLINGREA
Prev Close
658.25
Open Price
659.95
Volume
135,824
Today Low / High
626 / 663.25
52 WK Low / High
535.2 / 851.8
Range
607 - 671
Prev Close
657.75
Open Price
657.9
Volume
6,311
Today Low / High
626.05 / 662.95
52 WK Low / High
556.55 / 851.85
Range
603 - 666
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 638.6 (target range: 607 - 671), reflecting a change of -19.65 (-2.98519%). On the BSE, it is listed at 634.6 (target range: 603 - 666), showing a change of -23.15 (-3.51957%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Jubilant Ingrevia Limited Graph
Jubilant Ingrevia Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Jubilant Ingrevia Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 638.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 634.60 | 640.95 | 576.85 - 705.04 |
| 647.29 | 517.83 - 776.75 | ||
| 653.64 | 457.55 - 849.73 | ||
| Bearish Scenario | 634.60 | 628.25 | 565.43 - 691.08 |
| 621.91 | 497.53 - 746.29 | ||
| 615.56 | 430.89 - 800.23 |
Overview of Jubilant Ingrevia Limited
ISIN
INE0BY001018
Industry
Biotechnology
Vol.Avg
250,401
Market Cap
100,905,751,161
Last Dividend
5
Official Website
IPO Date
2021-03-19
DCF Diff
53.36
DCF
585
Financial Ratios Every Investor Needs
Stock Dividend of JUBLINGREA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 2.5 | 2.5 | 2025-07-25 | 2025-09-28 | |
| 2025-02-03 | February 03, 25 | 2.5 | 2.5 | 2025-02-03 | 2025-02-26 | |
| 2024-08-02 | August 02, 24 | 2.5 | 2.5 | 2024-08-02 | 2024-09-29 | |
| 2024-02-09 | February 09, 24 | 2.5 | 2.5 | 2024-02-09 | 2024-02-28 | |
| 2023-08-10 | August 10, 23 | 2.5 | 2.5 | 2023-08-10 | 2023-09-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,177.61 Cr | 2,570.81 Cr | 1,606.80 Cr | 0.3846 | 31.53 Cr | 420.88 Cr | 368.06 Cr | 251.17 Cr | 15.89 | 556.88 Cr | 0.0601 |
| 2024-03-31 | 4,135.80 Cr | 2,238.18 Cr | 1,897.61 Cr | 0.4588 | 29.51 Cr | 80.80 Cr | 299.94 Cr | 182.89 Cr | 11.56 | 456.42 Cr | 0.0442 |
| 2023-03-31 | 4,772.69 Cr | 2,581.57 Cr | 2,044.09 Cr | 0.4283 | 25.30 Cr | 44.84 Cr | 444.10 Cr | 307.50 Cr | 19.34 | 580.51 Cr | 0.0644 |
| 2022-03-31 | 4,949.36 Cr | 2,958.48 Cr | 1,955.95 Cr | 0.3952 | 0.00 Cr | 45.82 Cr | 734.09 Cr | 476.71 Cr | 29.98 | 863.32 Cr | 0.0963 |
| 2021-03-31 | 683.45 Cr | 546.45 Cr | 136.99 Cr | 0.2004 | 0.00 Cr | 6.38 Cr | 97.76 Cr | 54.36 Cr | 20.78 | 106.78 Cr | 0.0795 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 98.73 Cr | 5,031.77 Cr | 2,104.69 Cr | 2,927.0800 Cr | 763.78 Cr | 665.05 Cr | 943.42 Cr | 3,082.97 Cr | 0.00 Cr | 0.00 Cr | 20.50 Cr | 1,401.0000 Cr |
| 2024-03-31 | 78.78 Cr | 4,731.89 Cr | 1,994.42 Cr | 2,737.4740 Cr | 740.24 Cr | 661.46 Cr | 941.30 Cr | 2,849.63 Cr | 11.46 Cr | 4.38 Cr | 15.49 Cr | 1,286.0760 Cr |
| 2023-03-31 | 72.73 Cr | 4,258.88 Cr | 1,592.65 Cr | 2,666.2300 Cr | 406.75 Cr | 334.02 Cr | 1,035.11 Cr | 2,356.90 Cr | 109.66 Cr | 216.13 Cr | 8.24 Cr | 1,179.5800 Cr |
| 2022-03-31 | 37.46 Cr | 3,797.15 Cr | 1,364.08 Cr | 2,433.0680 Cr | 237.84 Cr | 200.38 Cr | 911.16 Cr | 1,958.28 Cr | 101.42 Cr | 67.93 Cr | 6.19 Cr | 1,052.7780 Cr |
| 2021-03-31 | 73.34 Cr | 3,378.52 Cr | 1,455.58 Cr | 1,922.9390 Cr | 555.67 Cr | 482.33 Cr | 609.10 Cr | 1,857.16 Cr | 105.77 Cr | 0.00 Cr | 53.87 Cr | 894.3340 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 508.0900 Cr | -392.8000 Cr | -128.7600 Cr | 142.3100 Cr | -9.4200 Cr | 69.3600 Cr | -365.7800 Cr | 251.1700 Cr | 23.5200 Cr | -79.7700 Cr | -2.1100 Cr |
| 2024-03-31 | 429.9790 Cr | -569.5020 Cr | 144.1340 Cr | -138.3960 Cr | 6.0590 Cr | 78.7840 Cr | -568.3750 Cr | 267.6110 Cr | 336.2730 Cr | -78.6210 Cr | 93.0300 Cr |
| 2023-03-31 | 462.4600 Cr | -471.8900 Cr | 41.6000 Cr | -18.9300 Cr | 35.1200 Cr | 72.7300 Cr | -481.3900 Cr | 436.7100 Cr | 167.6630 Cr | -79.3130 Cr | -125.8400 Cr |
| 2022-03-31 | 452.7380 Cr | -71.8560 Cr | -417.7520 Cr | 222.5890 Cr | -35.7340 Cr | 37.6080 Cr | -230.1490 Cr | 708.9410 Cr | -318.7480 Cr | -45.1550 Cr | -304.9470 Cr |
| 2021-03-31 | 102.8540 Cr | -43.6550 Cr | -72.3650 Cr | 84.7360 Cr | 73.2920 Cr | 73.3420 Cr | -27.5450 Cr | 77.3870 Cr | -62.1880 Cr | 0.0000 Cr | -37.4140 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1,120.73 Cr | 855.87 Cr | 264.86 Cr | 0.2363 | 94.29 Cr | 69.47 Cr | 4.40 | 146.33 Cr | 0.0620 |
| 2025-06-30 | 1,029.42 Cr | 519.44 Cr | 509.98 Cr | 0.4954 | 101.30 Cr | 75.10 Cr | 4.75 | 153.30 Cr | 0.0730 |
| 2025-03-31 | 1,038.16 Cr | 532.94 Cr | 505.22 Cr | 0.4866 | 107.30 Cr | 74.05 Cr | 4.69 | 155.08 Cr | 0.0713 |
| 2024-12-31 | 1,046.06 Cr | 538.63 Cr | 507.43 Cr | 0.4851 | 98.53 Cr | 69.38 Cr | 4.39 | 147.73 Cr | 0.0663 |
| 2024-09-30 | 1,045.24 Cr | 786.68 Cr | 258.56 Cr | 0.2474 | 84.97 Cr | 59.00 Cr | 3.73 | 134.89 Cr | 0.0564 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 46.91 Cr | 0.00 Cr | 46.91 Cr | 760.39 Cr | 927.81 Cr | 1,938.67 Cr | 3,223.65 Cr | 5,256.57 Cr | 2,215.72 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 114.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,927.08 Cr |
| 2025-03-31 | 98.73 Cr | 16.21 Cr | 114.94 Cr | 607.45 Cr | 943.42 Cr | 1,853.23 Cr | 3,082.97 Cr | 5,031.77 Cr | 2,104.69 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 62.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,815.36 Cr |
| 2024-09-30 | 62.62 Cr | 0.00 Cr | 62.62 Cr | 591.80 Cr | 889.37 Cr | 1,778.65 Cr | 2,975.13 Cr | 4,841.29 Cr | 2,025.94 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 75.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 74.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 69.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 59.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 48.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹366.20 | ₹472,078,252,104.00 | ₹1,894,679.00 |
| Anthem Biosciences Ltd. | ANTHEM | ₹608.90 | ₹341,964,360,054.00 | ₹161,152.00 |
| Syngene International Limited | SYNGENE | ₹543.80 | ₹218,472,620,139.00 | ₹4,137,761.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹151.41 | ₹200,371,055,914.00 | ₹2,742,599.00 |
| Onesource Specialty Pharma Ltd. | ONESOURCE | ₹1,432.40 | ₹164,131,754,536.00 | ₹727,984.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,247.90 | ₹130,550,560,972.00 | ₹84,026.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹638.60 | ₹100,905,751,161.00 | ₹135,824.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹432.45 | ₹75,015,123,041.00 | ₹348,820.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹716.05 | ₹57,629,708,940.00 | ₹112,575.00 |
| Zota Health Care Limited | ZOTA | ₹1,314.20 | ₹39,863,175,201.00 | ₹79,996.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹209.32 | ₹32,817,837,445.00 | ₹193,721.00 |
Key Executives
Gender: male
Year Born:
Gender: male
Year Born: 1975
Gender: male
Year Born: 1981
Gender: male
Year Born: 1956
Gender: male
Year Born:
Gender: male
Year Born: 1966
Gender: male
Year Born:
Gender: male
Year Born: 1976
Gender: female
Year Born:
Gender: female
Year Born: 1972
FAQs about Jubilant Ingrevia Limited
The CEO is Deepak Jain.
The current price is ₹638.60.
The range is ₹535.2-851.8.
The market capitalization is ₹10,090.58 crores.
The dividend yield is 0.78%.
The P/E ratio is 35.03.
The company operates in the Healthcare sector.
Overview of Jubilant Ingrevia Limited (ISIN: INE0BY001018) is a leading Biotechnology in India. With a market capitalization of ₹10,090.58 crores and an average daily volume of 250,401 shares, it operates in the Biotechnology. The company last declared a dividend of ₹5.